Format

Send to

Choose Destination
Cell Mol Life Sci. 2019 Feb 5. doi: 10.1007/s00018-019-03019-2. [Epub ahead of print]

Therapeutic potential of menstrual blood-derived endometrial stem cells in cardiac diseases.

Liu Y1,2, Niu R1, Li W3, Lin J4, Stamm C5,6,7,8, Steinhoff G9, Ma N2,9,10.

Author information

1
Stem Cell and Biotherapy Technology Research Center, College of Life Science and Technology, Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang, 453003, People's Republic of China.
2
Institute of Chemistry and Biochemistry, Free University Berlin, 14195, Berlin, Germany.
3
Institute of Chemistry and Biochemistry, Free University Berlin, 14195, Berlin, Germany. fuli@zedat.fu-berlin.de.
4
Stem Cell and Biotherapy Technology Research Center, College of Life Science and Technology, Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang, 453003, People's Republic of China. linjtlin@126.com.
5
Deutsches Herzzentrum Berlin (DHZB), Berlin, Germany.
6
German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.
7
Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
8
Berlin Institute of Health, Berlin, Germany.
9
Department of Cardiac Surgery, Reference and Translation Center for Cardiac Stem Cell Therapy, University Rostock, 18055, Rostock, Germany.
10
Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies, Helmholtz-Zentrum Geesthacht, 14513, Teltow, Germany.

Abstract

Despite significant developments in medical and surgical strategies, cardiac diseases remain the leading causes of morbidity and mortality worldwide. Numerous studies involving preclinical and clinical trials have confirmed that stem cell transplantation can help improve cardiac function and regenerate damaged cardiac tissue, and stem cells isolated from bone marrow, heart tissue, adipose tissue and umbilical cord are the primary candidates for transplantation. During the past decade, menstrual blood-derived endometrial stem cells (MenSCs) have gradually become a promising alternative for stem cell-based therapy due to their comprehensive advantages, which include their ability to be periodically and non-invasively collected, their abundant source material, their ability to be regularly donated, their superior proliferative capacity and their ability to be used for autologous transplantation. MenSCs have shown positive therapeutic potential for the treatment of various diseases. Therefore, aside from a brief introduction of the biological characteristics of MenSCs, this review focuses on the progress being made in evaluating the functional improvement of damaged cardiac tissue after MenSC transplantation through preclinical and clinical studies. Based on published reports, we conclude that the paracrine effect, transdifferentiation and immunomodulation by MenSC promote both regeneration of damaged myocardium and improvement of cardiac function.

KEYWORDS:

Cardiac disease; Cardiac regeneration; Menstrual blood-derived endometrial stem cells; Stem cell-based therapy

PMID:
30721319
DOI:
10.1007/s00018-019-03019-2

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center